PMN (promisneurosciences.com) Company Cash Funds

PMN (promisneurosciences.com) - company brandmark

ProMIS Neurosciences (PMN) maintains a high reputation for developing precision therapies for neurodegeneration targeting harmful brain proteins. The cash balance history demonstrates the business's liquidity, while the 0.04 metric reflects current dynamics. Intellectual capital regarding Alzheimer's disease treatment paves the way for licensing agreements, although the absence of commercial sales temporarily precludes pricing power.

Company Cash on Hand: ProMIS Neurosciences (PMN) for 06/27/2023 - 11/21/2026

Analytical breakdowns and data insights for company ProMIS Neurosciences, Inc. (PMN)

- stock value and consensus price forecast:
Fundamental valuation:PMN promisneurosciences.com
Signature product of promisneurosciences.com

This indicator measures the volume of liquid assets, determining the business's ability to maintain operational activities and weather market downturns without external borrowing. By analyzing the amount of cash resources, an investor assesses the company's resilience to interest rate changes, which is critical for ProMIS Neurosciences (PMN) during a period of costly antibody clinical trials, where controlling the burn rate of R&D capital directly impacts the issuer's survival.